Radiofrequency Ablation for Amiodarone-induced Thyrotoxicosis

Inclusion Criteria: * Are adults * Have overt thyrotoxicosis (within 2 weeks prior to enrollment) * Are receiving medical therapy for AIT * Are able to understand the study procedures and to comply with them for the entire length of the study * Have not normalized their thyroid levels after one month of standard therapy or * Have persistent and clinically significant thyrotoxicosis (less than 25% decrease in T4 value or patients requiring hospitalization with Congestive heart failure (CHF), tachyarrhythmias, hemodynamic instability or similar co-morbidities) after 2 weeks of standard therapy where additional medical therapy is deemed unlikely to be beneficial or with high risk of side-effects (e.g. hepatotoxicity of antithyroid medications, agranulocytosis of potassium perchlorate or ATD or fluid retention associated with steroids). Exclusion Criteria: * Pregnancy * Patients with prior neck surgery or neck radiation * Patients with neck anatomy that precludes easy access by RFA to the entirety of thyroid parenchyma * Patients on anticoagulation therapy * Patients with comorbidities deemed too high of a risk for general anesthesia * Treatment with another investigational drug or intervention (within 6 weeks of planned RFA). * Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * Inability or unwillingness of individual or legal guardian/representative to give written informed consent.